Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

NCT06724042 is registered in ClinicalTrials.gov with InSilico Medicine Hong Kong Limited as lead sponsor.

NCT NCT06724042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
Lead sponsor
InSilico Medicine Hong Kong Limited
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 30, 2026
Completion date
December 30, 2030
Enrollment
159 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumors, advanced solid tumor, metastatic solid tumor